News about Stryker

Procter & Gamble has raised its dividend annually for 70 consecutive years, and in fiscal 2026 it generated about $87 billion in net sales (up 3%), $16.1 billion in net earnings and $19.6 billion in operating cash flow. The company returned more than $15 billion to shareholders, including $10.2 billion in dividends and $5 billion in buybacks, though organic sales grew only 1%. Stryker, a medical technology maker of products such as artificial hips and knees and the Mako robotic surgery platform, reported Q2 2026 revenue of $6.6 billion (up 9.4%) and adjusted EPS up 17.9% to $3.69. The article argues that an aging population should support demand for Stryker's products, with Americans aged 65 and older projected to reach about 82 million by 2050. It concludes that P&G offers stability and dependable income, while Stryker offers exposure to a growing healthcare market.